Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease.
about
Insights and ideas garnered from marine metabolites for development of dual-function acetylcholinesterase and amyloid-β aggregation inhibitorsOur "energy-Ca(2+) signaling deficits" hypothesis and its explanatory potential for key features of Alzheimer's disease.M1 muscarinic receptor activation mediates cell death in M1-HEK293 cellsmGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivoDiscovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.Amyloid-β(25-35) Modulates the Expression of GirK and KCNQ Channel Genes in the Hippocampus.Translational Concepts of mGluR5 in Synaptic Diseases of the BrainPreface.Curcumin: a natural substance with potential efficacy in Alzheimer's disease.Learning history and cholinergic modulation in the dorsal hippocampus are necessary for rats to infer the status of a hidden event.Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsNeurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Aβ in vivo.Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease.Novel M(1) allosteric ligands: a patent review.Wnt signaling: role in Alzheimer disease and schizophrenia.Molecular Neurobiology of Depression: PET Findings on the Elusive Correlation with Symptom Severity.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.M1 muscarinic acetylcholine receptor in Alzheimer's diseaseInsights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes.Protein Kinase C Activation as a Potential Therapeutic Strategy in Alzheimer's Disease: Is there a Role for Embryonic Lethal Abnormal Vision-like Proteins?Synaptic signalling and its interface with neuropathologies: snapshots from the past, present and future.Cadmium-induced cell death of basal forebrain cholinergic neurons mediated by muscarinic M1 receptor blockade, increase in GSK-3β enzyme, β-amyloid and tau protein levels.Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions.Theory of Visual Attention (TVA) applied to mice in the 5-choice serial reaction time task.[11C]AF150(S), an agonist PET ligand for M1 muscarinic acetylcholine receptors.Noradrenergic sympathetic sprouting and cholinergic reinnervation maintains non-amyloidogenic processing of AβPP.Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission.Cholinergic neurons-keeping check on amyloid β in the cerebral cortex.Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.Adenosine A(2A) receptors are necessary and sufficient to trigger memory impairment in adult mice.Molecular mechanism for muscarinic M1 receptor-mediated endocytosis of TWIK-related acid-sensitive K+ 1 channels in rat adrenal medullary cells.Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study.Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia.Ameliorative effect of kolaviron, a biflavonoid complex from Garcinia kola seeds against scopolamine-induced memory impairment in rats: role of antioxidant defense system.Therapeutics of Neurotransmitters in Alzheimer's Disease.Acute Down-regulation of BDNF Signaling Does Not Replicate Exacerbated Amyloid-β Levels and Cognitive Impairment Induced by Cholinergic Basal Forebrain Lesion.Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease.Enhancing the Reliability of GPCR Models by Accounting for Flexibility of Their Pro-Containing Helices: the Case of the Human mAChR1 Receptor.Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model.
P2860
Q33575660-1418BC4E-5D5D-4ED4-9B8A-E125485B45E6Q34620989-6F66BE97-C1C7-44D9-83FA-635F2E267351Q34983868-62B0AB93-CB49-462F-9082-2CA9BE975F35Q35160799-25D90C3C-A3A2-42F8-812C-E2D8DFDCD39BQ35461842-2553B879-05D7-49D3-903D-3F2B33B39F29Q35719617-2FB2CB83-1CAD-472A-A040-4459B887DD79Q36424785-51086C7F-0ABC-47E6-940A-F8D009A48F81Q36717105-F49E75CA-9A54-4B39-9721-5C3D080AAE07Q36891064-2A2664C1-3069-4386-BF45-342B507CEF90Q36900884-6C5F75D3-875A-4E92-94A9-1AC66227E49EQ37025888-F990893C-AA21-48D3-B194-77A60160B03BQ37350693-6F9AC096-6DAF-40EF-AAAE-B3D8E712781DQ37559812-C7F64E47-8B9B-4225-A5A4-E84204EFBADCQ38054855-34FE7635-F406-4E3C-A70B-C78A712A3E93Q38060562-92F1C7C9-AC0D-4F20-B764-FEF64FF5BEB2Q38086422-2366295C-9104-40D5-B923-ED63B590F3F8Q38127470-E71184BD-739B-4800-B60F-FE3A5F4F5354Q38192962-00600130-B5C7-4D24-8AD6-1E2D9FC16855Q38247995-A5B0BD36-8BB5-45BF-B5D9-61A4D123E6F9Q38784086-E1A9310C-19C8-4581-95A2-D0D406A268B5Q38802640-3ED1253E-3902-458C-93E8-F5B2368994FAQ38869291-26C54EDD-9532-4A0B-898F-1F1C8FD244D0Q38960486-4E63B14E-8DD3-4802-93A5-B74A990D0198Q39030164-2599CC1B-5AD4-43DC-99F4-9167AF5AC929Q39774300-87F83255-C03E-4B66-815C-E1E2ECC39960Q40390510-DDD824EE-9F5A-4EC5-97F4-F55CFF6B23C3Q40909041-D49B1173-1362-4E72-9E6C-06E29D2A089BQ41938645-ADD7ECD0-A90D-4BA9-9EEE-4EC5281CE267Q42020086-AC70F33D-5971-461C-818D-10187EEA7AB5Q42412786-E0BC35CB-1649-4214-BF10-72B26504CD41Q47750220-FA05E552-43DA-4C4F-92E4-2D6C44119212Q48226341-E020EAF5-538A-42F0-A880-2960FF2A7DF8Q48468765-ED54B5B5-6307-426C-83F0-52FF02C9E4FAQ48511914-DCBAA992-B38B-4049-AF5D-370B0670E856Q49672905-0D2B6298-6577-481E-B858-5A9B5573D3B6Q50531667-118933F6-1072-4F49-9FDB-C7408908EE0AQ50738123-B236D613-12E2-4CF9-8711-27AEADEAD8C4Q50940415-A471CAAE-E85F-4D37-8E39-8D85DD7817ACQ53347422-B4B1F075-9893-4CAF-B842-1813ACD0214AQ55073637-9E9F9D6A-B089-4A91-9892-CB4DDFD89270
P2860
Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Cholinergic modulation of amyl ...... atment of Alzheimer's disease.
@en
Cholinergic modulation of amyl ...... atment of Alzheimer's disease.
@nl
type
label
Cholinergic modulation of amyl ...... atment of Alzheimer's disease.
@en
Cholinergic modulation of amyl ...... atment of Alzheimer's disease.
@nl
prefLabel
Cholinergic modulation of amyl ...... atment of Alzheimer's disease.
@en
Cholinergic modulation of amyl ...... atment of Alzheimer's disease.
@nl
P2860
P1476
Cholinergic modulation of amyl ...... atment of Alzheimer's disease.
@en
P2093
Abraham Fisher
P2860
P356
10.1111/J.1471-4159.2011.07507.X
P407
P478
120 Suppl 1
P577
2011-11-28T00:00:00Z